[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60237448D1 - Verfahren zur diagnose oder prognostizierung der wesentlichen bakteriellen erreger von atemwegserkrankungen in einem patienten - Google Patents

Verfahren zur diagnose oder prognostizierung der wesentlichen bakteriellen erreger von atemwegserkrankungen in einem patienten

Info

Publication number
DE60237448D1
DE60237448D1 DE60237448T DE60237448T DE60237448D1 DE 60237448 D1 DE60237448 D1 DE 60237448D1 DE 60237448 T DE60237448 T DE 60237448T DE 60237448 T DE60237448 T DE 60237448T DE 60237448 D1 DE60237448 D1 DE 60237448D1
Authority
DE
Germany
Prior art keywords
inflammators
prognostication
diagnosis
patient
respiratory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237448T
Other languages
English (en)
Inventor
Jesper Eugen-Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViroGates ApS
Original Assignee
ViroGates ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViroGates ApS filed Critical ViroGates ApS
Application granted granted Critical
Publication of DE60237448D1 publication Critical patent/DE60237448D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60237448T 2001-05-18 2002-05-21 Verfahren zur diagnose oder prognostizierung der wesentlichen bakteriellen erreger von atemwegserkrankungen in einem patienten Expired - Lifetime DE60237448D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100799 2001-05-18
PCT/DK2002/000341 WO2002095411A1 (en) 2001-05-18 2002-05-21 A method of diagnosing or prognosticating major respiratory bacterial pathogens in a subject

Publications (1)

Publication Number Publication Date
DE60237448D1 true DE60237448D1 (de) 2010-10-07

Family

ID=8160511

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237448T Expired - Lifetime DE60237448D1 (de) 2001-05-18 2002-05-21 Verfahren zur diagnose oder prognostizierung der wesentlichen bakteriellen erreger von atemwegserkrankungen in einem patienten

Country Status (11)

Country Link
US (1) US7399602B2 (de)
EP (1) EP1405076B1 (de)
CN (1) CN100340858C (de)
AT (1) ATE479097T1 (de)
BR (1) BRPI0210903B8 (de)
DE (1) DE60237448D1 (de)
DK (1) DK1405076T3 (de)
EA (1) EA005776B1 (de)
ES (1) ES2351690T3 (de)
WO (1) WO2002095411A1 (de)
ZA (1) ZA200309770B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1234178B1 (de) 1999-11-25 2007-08-01 Jesper Eugen-Olsen Verfahren zur diagnose oder prognose einer hiv infektion in einem patienten
US20060084184A1 (en) * 2004-10-19 2006-04-20 Renovar Incorporated Reagents for urine-based immunological assays
CN101925819B (zh) * 2007-12-28 2013-06-12 株式会社比尔生命 结核分歧杆菌复合群的免疫检出方法
AU2012256683B2 (en) * 2011-05-19 2017-02-02 Mochida Pharmaceutical Co., Ltd. Diagnosis of respiratory tract infectious diseases using urine specimens
GB201211982D0 (en) * 2012-07-05 2012-08-22 Isis Innovation Biomarker
AP2016009538A0 (en) * 2014-04-15 2016-11-30 Univ Stellenbosch A method for diagnosing tuberculous meningitis
EP3177312B1 (de) * 2014-08-08 2020-12-30 Randox Laboratories Ltd. Verfahren und kit zum nachweis von bakterieller infektion
CN106556703A (zh) * 2016-10-18 2017-04-05 上海凯璟生物科技有限公司 一种慢性肾脏病标志物suPAR检测试剂盒和制备方法
RU2659384C1 (ru) * 2017-07-10 2018-06-29 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Способ раннего прогнозирования характера течения острой респираторной инфекции у детей
GB201802795D0 (en) * 2018-02-21 2018-04-04 Virogates As Patient assessment method
FR3080185A1 (fr) * 2018-04-16 2019-10-18 Biomerieux Evaluation du risque de complication chez un patient suspecte d'avoir une infection ayant un score sofa inferieur a deux
CN115516314A (zh) * 2020-04-08 2022-12-23 维罗盖茨有限公司 Sars-cov-2感染风险评估方法
RU2765744C2 (ru) * 2020-07-20 2022-02-02 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ определения вероятности летального исхода на основании жалоб у больного туберкулезом с ВИЧ-инфекцией при поступлении в стационар Федеральной службы исполнения наказаний РФ
CN113295874B (zh) * 2021-05-25 2022-03-04 广东源心再生医学有限公司 一种用于瓣膜性心脏病辅助诊断的新型标志物、辅助诊断的产品

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845026A (en) 1985-12-03 1989-07-04 T Cell Sciences, Inc. Assay systems for detecting cell-free T cell antigen receptor related molecules and the clinical utilities of the assays
US5459078A (en) 1988-01-29 1995-10-17 Abbott Laboratories Methods and reagents for performing ion-capture digoxin assays
CN1289409A (zh) 1998-01-26 2001-03-28 澳洲生物科技公司 PAI－2和t－PA作为牙周病的诊断指标
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
DE19840671A1 (de) 1998-08-26 2000-03-02 Stiftung Tumorbank Basel Verfahren zur Diagnose von Rezidiven bei nodal-negativem Brustkrebs
CA2384295A1 (en) 1999-04-28 2000-11-02 Yahia Gawad Method for determining plasminogen activator inhibitor
EP1234178B1 (de) 1999-11-25 2007-08-01 Jesper Eugen-Olsen Verfahren zur diagnose oder prognose einer hiv infektion in einem patienten

Also Published As

Publication number Publication date
BRPI0210903B1 (pt) 2017-01-17
CN100340858C (zh) 2007-10-03
EP1405076B1 (de) 2010-08-25
EA200301271A1 (ru) 2004-06-24
EP1405076A1 (de) 2004-04-07
BRPI0210903B8 (pt) 2021-07-27
CN1723394A (zh) 2006-01-18
ES2351690T3 (es) 2011-02-09
ATE479097T1 (de) 2010-09-15
ZA200309770B (en) 2004-09-28
BR0210903A (pt) 2004-06-08
WO2002095411A1 (en) 2002-11-28
US7399602B2 (en) 2008-07-15
EA005776B1 (ru) 2005-06-30
DK1405076T3 (da) 2011-01-03
US20050100961A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
DE60237448D1 (de) Verfahren zur diagnose oder prognostizierung der wesentlichen bakteriellen erreger von atemwegserkrankungen in einem patienten
Gupta et al. Role of salivary matrix metalloproteinase-8 (MMP-8) in chronic periodontitis diagnosis
WO2022056313A3 (en) Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
DE60025526D1 (de) Elisa für vegf
AU2002341191A1 (en) Diagnosis of clinical infection of a wound
WO2002053028A8 (en) Electrical impedance method and apparatus for detecting and diagnosing diseases
WO2006073682A3 (en) Diagnostic test
EP1221620A3 (de) Verfahren zum Ausführen einer Bestimmung der "activated clotting time" mit geringer Empfindlichkeit gegenüber die Anwesenheit des Aprotinins sowie zur Ermittlung der Aprotinin-Empfindlichkeit
Bick et al. Fibrinolytic activity in acute myocardial infarction
AU2392692A (en) Method and kit for measuring endogenous cytokines
Kim et al. Validation of periodontitis screening model using sociodemographic, systemic, and molecular information in a Korean population
ATE529743T1 (de) Verfahren und kits zur tumorigenizitätsdiagnose
AP1623A (en) A method of diagnosing of prognosticating HIV infection in a subject.
WO2020023789A3 (en) Small rna predictors for alzheimer's disease
ATE335434T1 (de) Vorrichtung und verfahren zur messung der vaskulären impedanz
DE3875826D1 (de) Methode, vorrichtung und testsatz zur messung der aktivitaet eines gewebeplasminogenaktivators.
AU2001283795A1 (en) Simple methods for the drug monitoring of gpiib/iiia-receptor antagonists
WO2003014394A1 (fr) Methode d'evaluation de la biocompatibilite
DE60203524D1 (de) Verfahren zur messung des arteriolendrucks
Faraj et al. Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
Pan et al. Effects of wearable physical activity tracking for breast cancer survivors: A systematic review and meta‐analysis
DE60144027D1 (de) 5t4 rna in plasma und serum als marker für neoplastische erkrankungen
ATE370243T1 (de) Screeningverfahren für einen auf die zellwand wirkenden arzneistoff
Sorensen et al. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
CN106805959A (zh) 具有测量血压功能的机器人装置

Legal Events

Date Code Title Description
R082 Change of representative

Ref document number: 1405076

Country of ref document: EP

Representative=s name: HOFFMANN & EITLE, 81925 MUENCHEN, DE